Insulin resistance syndrome: interaction with coagulation and fibrinolysis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Insulin resistance represents a common metabolic abnormality leading to cardiovascular disease, the major cause of morbidity and mortality in most parts of the world. Insulin resistance is also associated with an increased risk of type 2 diabetes which is strongly associated with obesity. The insulin resistance of obese people and subjects with type 2 diabetes is characterised by defects at many levels, affecting insulin receptor concentration, glucose transport mechanisms and the activities of intracellular enzymes. Around 25% of western populations show some features of the insulin resistance syndrome (often referred to as syndrome X or the metabolic syndrome) ie, a clustering of metabolic, atheromatous risk factors, including hypertriglyceridaemia, hyperinsulinaemia, hyper-tension, hypercholesterinaemia and obesity. However, the known metabolic cardiovascular risk factors associated with the insulin resistance syndrome do not sufficiently explain the excess vascular risk attributed to this syndrome. The observation, that increased plasma plasminogen activator inhibitor 1 (PAI-1) levels were associated with insulin resistance and atherothrombosis added for the first time a pathological basis for an association of the insulin resistance syndrome not only with metabolic, atheromatous (atherosclerotic) risk but also with atherothrombotic risk. It is very likely that not only PAI-1, but also other abnormalities in haemostatic variables contribute to this excess vascular risk. Knowledge of how haemostatic variables cluster with classical metabolic risk factors associated with the insulin resistance syndrome could help to better understand the pathogenesis of cardiovascular diseases. Indeed, many coagulation and fibrinolytic proteins have been shown to be associated with features of the insulin resistance syndrome and these associations suggest that some coagulation and fibrinolytic proteins have a role in atherothrombotic disorders, principally through an association with other established metabolic (atheromatous) risk factors in the presence of underlying insulin resistance. Interestingly, new therapeutic approaches in the prevention and treatment of insulin resistance do show some influence on coagulation and fibrinolysis. The newest drugs are the thiazolidinediones, a totally novel class of insulin sensitisers. They have the potential to offer improvements both in glycaemic control and in cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Signaling pathways in insulin action: molecular targets of insulin resistance
Pessin, J. E., & Saltiel, A. R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10582 · Cited by 939
Laakso, M., Edelman, S. V., Brechtel, G., & Baron, A. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114644 · Cited by 930
Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602
Heinrich, J., Balleisen, L., Schulte, H., Assmann, G., & van de Loo, J. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.54 · Cited by 563
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors
FOLSOM, A., WU, K., DAVIS, C., CONLAN, M., SORLIE, P., & SZKLO, M. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90167-2 · Cited by 321
Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200743200 · Cited by 319
Nagi, D. K., Hendra, T. J., Ryle, A. J., Cooper, T. M., Temple, R. C., Clark, P. M. S., Schneider, A. E., Hales, C. N., & Yudkin, J. S. (1990) · Diabetologia · doi:10.1007/bf00404140 · Cited by 198
Eriksson, P., Nilsson, L., Karpe, F., & Hamsten, A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.1.20 · Cited by 187
Cited by
Innes, K. E., Bourguignon, C., & Taylor, A. G. (2005) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.18.6.491 · Cited by 425
Update on Bispectral Index monitoring
Johansen, J. W. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2005.08.004 · Cited by 313
Innes, K. E., & Vincent, H. K. (2007) · Evidence-Based Complementary and Alternative Medicine · doi:10.1093/ecam/nel103 · Cited by 268
Endothelial dysfunction in obesity
Engin, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-48382-5_15 · Cited by 255
Effects of VLDL and remnant particles on platelets.
Olufadi, R., & Byrne, C. D. (2006) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000093221 · Cited by 111
Metabolic syndrome and endothelial fibrinolytic capacity in obese adults
Van Guilder, G. P., Hoetzer, G. L., Greiner, J. J., Stauffer, B. L., & DeSouza, C. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00564.2007 · Cited by 29
Metadata
- Authors
- Weekly, S. M.
- Venue
- Swiss Medical Weekly
- Publisher
- SMW Supporting Association
- Published
- 2002-05-18
- Volume
- 132
- Issue
- 1920
- Pages
- 241-252
- ISSN
- 0036-7672 (ISSN-L)
- 1424-3997
- OpenAlex
- W78210398
- Cited by
- 94
- References
- 12
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.